<?xml version="1.0" encoding="UTF-8"?>
<p id="par0060">Additionally, a total of 382 human clinical or animal field specimens were screened with the pan-CoV assay, including 192 human swabs (collected from hospitalized pneumonia patients at Sibu and Kapit Hospitals of Sarawak, Malaysia) [
 <xref rid="bib0040" ref-type="bibr">8</xref>], 81 poultry swabs (collected from a live poultry market in Hanoi, Vietnam) [
 <xref rid="bib0045" ref-type="bibr">9</xref>], and 109 pig slurry samples (collected from pig farms in North Carolina, USA) [
 <xref rid="bib0050" ref-type="bibr">10</xref>]. These samples were supplemented with bioaerosol samples (n = 31) collected using the National Institute for Occupational Safety and Health’s (NIOSH, Morgantown, West Virginia, USA) model BC 251 two-stage bioaerosol sampler from a large poultry market in Vietnam [
 <xref rid="bib0045" ref-type="bibr">9</xref>]. Finally, we compared the pan-CoV assay’s performance to the US Center for Disease Control and Prevention’s 2019-nCoV RT-PCR assay [
 <xref rid="bib0055" ref-type="bibr">11</xref>] against a set of clinical specimens from COVID-19 patients.
</p>
